{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '-', 'Short acting nitrate.', 'IMP administration should be continued until the visit to the site.', 'The following assessments have to be performed:', 'Quality of life questionnaires should be filled in prior any other assessment and without', 'any help:', '-', 'Seattle Angina Questionnaire,', '-', \"Patients' perceptions of treatment and symptoms.\", 'Physical examination (including smoking habits).', 'Patient diary collection.', 'Body weight.', 'Body temperature.', 'Vital signs including search of orthostatic BP measurements and resting 12 lead-ECG.', 'Blood sampling for renal function (blood creatinine and cystatin C).', 'Blood sampling for hematology, biochemistry.', 'Collection of urine for urinalysis.', 'Collection of PK samples (pre-dose).', 'AEs collection.', 'Collection of information about any concomitant medications.', 'After IMP intake:', 'Coronary flow reserve assessed by vasodilator stress PET scan with NIMPs', 'administration, is performed approximately 1 to 2 hours after IMP intake.', 'Collection of PK samples (1-3h post-dose).', 'Call IVRS/IWRS to declare the end of treatment for this patient, except if patient has delay', 'in end-of-treatment PET scan.', 'If no clinically relevant findings have been detected from all safety examinations until then, the', \"patient can be discharged from the unit in the evening or earlier depending of the investigator's\", 'judgment.', 'Approximately seven days after the last study drug intake, the investigator will prescribe if needed', 'anti-anginal drugs (ie, nitrates) and/or PDE 5 inhibitor.', 'Only if PET scan performed after Day 29 visit, at home, the patient will take the IMP twice a day', '(morning and bedtime) and will report on his patient diary IMP information and the angina', 'episodes that will occur and short-acting nitroglycerin intakes.', 'In case of early IMP discontinuation:', 'Property of the Sanofi Group - strictly confidential', 'Page 66', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '-', 'Within the first 2 weeks of study treatment patients are to be assessed as soon as', 'possible after study drug stop, using the procedures (except PET scan) planned for the', 'D29/end of treatment visit, including a pharmacokinetic sample (to be collected no', 'later than 3 days after the last study drug intake).', '-', 'With at least 2 weeks of study treatment patients are to be assessed as soon as possible', 'after study drug stop, using the procedures planned for the D29/end of treatment visit,', 'including a pharmacokinetic sample (to be collected no later than 3 days after the last', 'study drug intake). PET scan can be performed up to 3 days after study drug', 'discontinuation.', '10.1.5 Visit 6: End of study: Day 36 (+/-2 days)', 'Visit at clinical site:', \"Patient's diary review.\", 'Vital signs (BP & heart rate measurements including search of hypotension) and resting', '12 lead ECG.', 'Blood sampling for hematology, biochemistry.', 'Blood sampling for renal function (blood creatinine and cystatin C).', 'AEs collection.', 'Collection of information about any concomitant medications.', 'Study restriction(s)', 'There is no restriction of meals with regard to contents or time schedule.', 'This visit is not mandatory in case of premature treatment discontinuation.', '10.2 DEFINITION OF SOURCE DATA', 'All evaluations listed below that are reported in the CRF must be supported by appropriately', 'signed identified source documentation related to:', 'Patient identification.', 'Medical/surgical history.', 'Dates and times of visits and assessments.', 'Physical examination, cardiological examination.', 'Vital signs, body weight and height, body temperature.', 'Resting 12-lead ECGs results.', 'Laboratory result.', 'Pharmacokinetic & Biomarker time points.', 'Property of the Sanofi Group - strictly confidential', 'Page 67', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Adverse events.', 'IMP administration.', 'Previous/concomitant medication, including start of medication and time of change in', 'dosing regimen.', 'SAQ.', \"PET scan CFR reports of assessments performed during the patient's study participation.\", 'CCTA results if any.', 'Coronary artery angiography results if any.', \"Patient's diaries.\", 'Patient perceptions of treatment and symptoms.', 'Resources utilization.', '10.3 HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT', 'DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION', 'The IMP should be continued whenever possible. Permanent IMP discontinuation should be a last', 'resort. Any IMP discontinuation should be fully documented in the CRF. In any case, the patient', 'should remain in the study as long as possible.', 'Pregnancy will lead to definitive treatment discontinuation in all cases.', 'Additional stopping rules described in Appendix A and Section 8.1 should be applied,', 'if applicable.', '10.3.1 Temporary treatment discontinuation with investigational medicinal product(s)', 'Not applicable.', '10.3.2 Permanent treatment discontinuation with investigational medicinal product(s)', 'Permanent treatment discontinuation is any treatment discontinuation associated with the', 'definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at', 'any time. List of criteria for permanent treatment discontinuation', 'The patients may withdraw from treatment with the IMP if they decide to do so, at any time and', \"irrespective of the reason, or this may be the Investigator's decision. All efforts should be made to\", 'document the reason(s) for treatment discontinuation and this should be documented in the', 'e-CRF.', 'IMP may be permanently discontinued in case of the following events. The list is not intended to', 'be exhaustive:', 'Severe symptomatic orthostatic hypotension or postural dizziness (defined as requiring', 'medical intervention or hospitalization) (see Section 10.4.5).', 'Property of the Sanofi Group - strictly confidential', 'Page 68', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}